Balaglitazone

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBalaglitazone
Drug Alias Namebalaglitazona巴格列酮balaglitazonebalaglitazonumNN-2344 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmarkMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesDr.Reddy's Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDr Reddy`S Branded Formulation Manufacturing IiRheoscience ApsRheoscience AS +[4] 
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A